Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow TITAN PHARMACEUTICALS INC

Get SEC filing alerts via email and in your feed for TITAN PHARMACEUTICALS INC

TTNP TTNPW

TITAN PHARMACEUTICALS INC

About TITAN PHARMACEUTICALS INC

Titan Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing long-term drug delivery systems, notably the ProNeura platform. Its products target chronic diseases, including opioid use disorder, through implantable therapies. The company operates primarily in the U.S. and Europe, emphasizing product development, regulatory approval, and strategic transactions to enhance value, while managing financial and operational challenges inherent in biotech innovation.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from TITAN PHARMACEUTICALS INC

1
1
TITAN PHARMACEUTICALS INC Titan Pharmaceuticals Reports Reduced Net Loss and Increased Assets for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

2
1
TITAN PHARMACEUTICALS INC Titan Pharmaceuticals Reports $563,000 Net Loss in Q1 2025, Sees Improvement Year-Over-Year

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
TITAN PHARMACEUTICALS INC Titan Pharmaceuticals Reports $4.7 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments